1. Home
  2. PGY vs MLYS Comparison

PGY vs MLYS Comparison

Compare PGY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGY
  • MLYS
  • Stock Information
  • Founded
  • PGY 2016
  • MLYS 2019
  • Country
  • PGY United States
  • MLYS United States
  • Employees
  • PGY N/A
  • MLYS N/A
  • Industry
  • PGY Finance: Consumer Services
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PGY Finance
  • MLYS Health Care
  • Exchange
  • PGY Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • PGY 707.8M
  • MLYS 634.6M
  • IPO Year
  • PGY N/A
  • MLYS 2023
  • Fundamental
  • Price
  • PGY $8.78
  • MLYS $9.24
  • Analyst Decision
  • PGY Buy
  • MLYS Strong Buy
  • Analyst Count
  • PGY 8
  • MLYS 2
  • Target Price
  • PGY $21.00
  • MLYS $30.00
  • AVG Volume (30 Days)
  • PGY 1.7M
  • MLYS 266.6K
  • Earning Date
  • PGY 02-19-2025
  • MLYS 11-11-2024
  • Dividend Yield
  • PGY N/A
  • MLYS N/A
  • EPS Growth
  • PGY N/A
  • MLYS N/A
  • EPS
  • PGY N/A
  • MLYS N/A
  • Revenue
  • PGY $970,898,000.00
  • MLYS N/A
  • Revenue This Year
  • PGY $26.59
  • MLYS N/A
  • Revenue Next Year
  • PGY $14.40
  • MLYS N/A
  • P/E Ratio
  • PGY N/A
  • MLYS N/A
  • Revenue Growth
  • PGY 23.38
  • MLYS N/A
  • 52 Week Low
  • PGY $8.20
  • MLYS $8.28
  • 52 Week High
  • PGY $20.00
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • PGY 42.09
  • MLYS 32.12
  • Support Level
  • PGY $8.27
  • MLYS $8.60
  • Resistance Level
  • PGY $9.23
  • MLYS $9.97
  • Average True Range (ATR)
  • PGY 0.63
  • MLYS 0.88
  • MACD
  • PGY -0.05
  • MLYS -0.31
  • Stochastic Oscillator
  • PGY 19.39
  • MLYS 13.25

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, big data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: